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Models of Neuroimmune and Neurodegenerative DiseasesAgeing is accompanied by decreased overall ﬁtness and
performance. Studying brain ageing in humans is chal-
lenging due to limited or no access to healthy tissue,
limited opportunities for interventions and complicat-
ed confounding factors. The generation of mouse age-
ing models with uniform genetic backgrounds
signiﬁcantly contributed to understanding (brain) age-
ing at the molecular level. Research has focused on
evolutionarily conserved mechanisms or pathways that
control ageing to facilitate data extrapolation to
humans. Understanding how these pathways contrib-
ute to pathological ageing may help us understand
human central nervous system (CNS) ageing and assist
in the development of possible therapeutic targets. In
this review, we focus on the functional consequences
and pathological changes in the CNS of ageing mouse
models.
Introduction
Ageing is the main risk factor for many neurodegenerative
diseases. Understanding how normal brain ageing transitions
to pathological ageing is of vital importance to develop
possible treatment for ageing associated central nervous sys-
tem (CNS) pathologies.*Corresponding author.: S.M. Kooistra (s.m.kooistra@umcg.nl)
1740-6757/$ © 2018 The Authors. Published by Elsevier Ltd. This is an open access article 
10.1016/j.ddmod.2018.10.002 Section editor:
Professor Sandra Amor – Department of Pathology,
Amsterdam UMC, VUMC site, 1081 HV Amsterdam,
The Netherlands.
To investigate CNS ageing, a range of ageing mouse models
was developed, in view of the genetic similarity between mice
and humans, their relatively short life span and amenability
for genetic manipulation [1]. Human and mouse brain ageing
exhibit many common features. On the pathological level,
brain atrophy, neuronal loss, neuronal lipofuscinosis and
reactive glial cells are observed following ageing in both
human and mouse brain [2]. On a functional level, both
humans and mice show an age-dependent decline in learning
and memory and motor performance [3]. On a transcription-
al level, common sets of genes are affected by ageing in mouse
and human [4]. On an epigenetic level, DNA methylation is
strongly correlated with ageing [5], and age-associated DNA
methylation changes are relatively well conserved between
humans and mice [6].
However, it is worth noting that there is very limited
correlation between age regulated gene expression changes
in mouse and human, indicating that the ageing process in
the CNS of human and mice might be quite different [7,8].
Given that age regulation is quite different in different tissues
and species [7], research has focused on evolutionarily con-
served mechanisms that control ageing to facilitate data
extrapolation to humans. These conserved pathways or
mechanisms include genomic instability, epigenetic altera-
tions, telomere attrition, mitochondrial dysfunction, loss of
proteostasis and nutrient sensing pathways etc. [9,10].under the CC BY license (http://creativecommons.org/licenses/by/4.0/). https://doi.org/
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CNS ageing and ageing-related diseases will be discussed with
the main focus on pathological changes during CNS ageing.
Mouse models with genomic instability
Brain ageing is characterized by loss of genomic integrity [11].
Excessive DNA damage and insufficient DNA repair both can
contribute to genomic instability during the ageing process
[12]. Numerous mouse models with genomic instability have
been established and extensively reviewed [13,14]. Here, we
only focus on models with CNS ageing phenotypes. Detailed
CNS phenotypes of these mice are described in Table 1.
Mouse models with excessive DNA damage
Atm-deﬁcient mice
Ataxia-telangiectasia(AT) isahumangeneticdisorder causedby
mutational inactivation of the ATM gene [15]. ATM plays a
major role in maintaining genomic stability and DNA strand
breaks accumulate in the brain of Atm/ mice [16]. ATM
dysfunction resulted in increased reactive oxygen species
(ROS) production, which may induce the degeneration of
cerebellar neurons [17]. The histological, immunohistochemi-
cal and electrophysiological properties of Purkinje cells (PCs)
werenotalteredincerebellum,however,thesecellsshowedage-
dependent defects in calcium spike bursts and calcium currents
[18]. Atm deficiency induced progressive loss of dopaminergic
neurons in the substantia nigra (SN) and GABAergic neurons in
the striatum (STR) [19]. Atm deficiency was also shown to
impair astrocyte-endothelial cell interactions, which could be
the underlying mechanism for neurodegeneration [20].
BubR1 deﬁcient mice
BubR1 is a mitotic checkpoint protein that is essential for the
accurate separation of duplicated chromosomes during cell
division. Reduced BubR1 expression induces aneuploidy,
which affects genomic stability [21]. BubR1 insufficient mice
(BubR1H/H mice) exhibited various motor deficits, including
impaired motor strength, coordination, gait patterns and re-
duced locomotor activity. BubR1 expression is significantly
reduced with natural ageing in the mouse brain, and BubR1H/H
mice exhibit age related decline in hippocampal neurogenesis
[22]. The oligodendrocyte progenitor cell proliferation and
oligodendrocyte density were markedly reduced in brain and
spinal cord, which further caused axonal hypomyelination
[23]. Besides, BubR1H/Hmicealsoshowedcerebraldegeneration
and accelerated gliosis in the brain [24].
DNA methyltransferase deﬁcient mice
DNA methyltransferase 1 (Dnmt1) is the most prevalent DNA
methyltransferase that maintains genomic methylation sta-
bility. Dnmt1 haploinsufficiency impaired learning and mem-
ory function in an age-dependent manner in mice [25]. In
addition, conditional deletion of Dnmt1 and Dnmt3a in22 www.drugdiscoverytoday.comneurons induced abnormal long-term plasticity in CA1 and
deficits of learning and memory; however, no neuronal loss
was observed [26].
DNA damage repair deﬁcient mice
DNA damage alters the structure of DNA and most DNA
damages undergo repair. Excess DNA damage is associated
with ageing and cancer. There are several DNA repair path-
ways for different types of DNA damage. Deficiencies in DNA
repair pathways cause progeria syndromes in humans and
also affect the CNS [27]. Several ageing mouse models were
established based on deletion or mutation of genes involved
in DNA repair pathways.
Ercc1 deﬁcient mice
Excision repair cross-complementation group 1 (ERCC1) is an
essential component of multiple DNA repair pathways: nu-
cleotide excision repair (NER), double-strand break repair and
interstrand cross-link repair pathways [28]. Mice carrying a
knock out and a hypomorpic allele for Ercc1 showed age-
dependent motor abnormalities and cognitive decline. Fur-
ther studies revealed widespread astrogliosis, microgliosis
and neuronal degeneration in the brain, and motor neuron
loss in the spinal cord [28,29]. The mutant mice did not show
altered synapse numbers and dendritic morphology in the
hippocampus. However, Ercc1D/ mice did show age-depen-
dent changes in the proteomic composition and synaptic
plasticity in the hippocampus [30]. A similar age-related
cognitive decline and neurodegeneration were also observed
in conditional knockout mice (Ercc1f/ CaMKII-Cre+ mice), in
which Ercc1 deficiency was directed to excitatory forebrain
neurons [28]. For microglia, we have shown that microglia in
Ercc1D/mice exhibit a hypertrophic morphology with thick-
ened primary processes and larger cell bodies at the age of 16
weeks. Functionally, Ercc1D/ microglia displayed increased
phagocytosis, proliferation and ROS production. Ercc1D/
microglia displayed an exaggerated proinflammatory re-
sponse to a systemic inflammatory lipopolysaccharide
(LPS) challenge, indicative of a ‘‘primed’’ state. Transcrip-
tome analysis also confirmed Ercc1D/microglia were primed,
with a clear phagocytic and chemotactic profile and en-
hanced immune state [31,32].
Xpg/ mice
The premature ageing syndrome Cockayne syndrome (CS) is
characterized by growth failure, abnormal sensitivity to light
and impaired development of the CNS [33]. In humans with
CS, the DNA repair gene XPG that is involved in NER,
homologous recombination repair and base excision repair
(BER) is mutated. Xpg/ mice exhibit multiple progressive
features of CNS ageing, such as loss of hearing and vision,
cognitive decline, motor deficits and early development of
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Abbreviations: KO, knockout; DA, dopamine; SN, substantia nigra; GABA, gamma-aminobutyric acid; PCs, Purkinje cells; AT, Ataxia-telangiectasia; GFAP, glial ﬁbrillary acidic protein; CA, cornu ammonis; ROS, reactive oxygen species; COFS, cerebro-
oculo-facio-skeletal; XP, xeroderma pigmentosum; Iba-1, ionized calcium-binding adapter molecule 1; CS, Cockayne syndrome; XPCS, xeroderma pigmentosum combined with Cockayne syndrome; TTD, trichothiodystrophy; DG, dentate gyrus;
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of age. At 14 weeks of age, astrogliosis was severe and associ-
ated with axonal swellings and loss of PCs in the cerebellum.
The genotoxic stress marker p53 was detected in neurons,
astrocytes and oligodendrocytes. Terminal deoxynucleotidyl
transferase dUTP nick end labeling (TUNEL) showed a signif-
icant increase in apoptotic cells in the cerebrum at 4 as well as
14 weeks of age [35].
Csa/ and Csb / mice
Csa and Csb are genes involved in transcription-coupled
excision repair (TCR) In Csa/ and Csb/ mice, activated
microglia and astrocytes are detected in the white matter.
However, microglia activation was not observed in NER-
deficient Xpa/ and Xpc/ mice. Therefore, next, TCR-
deficient mice were generated with selective NER deficiency
targeted to forebrain neurons. Csb//Xpac//CamKIIa-Cre
mice displayed dramatic age-related neuronal loss, behavioral
abnormalities, and brain atrophy in the forebrain [36].
Sirt6 deﬁcient mice
Sirtuins (SIRT1–SIRT7) are an evolutionally conserved family of
NAD+-dependent deacetylases, and play a critical role in brain
ageing and neurodegenerative diseases [37]. SIRT6 promotes
DNA repair and its activity declines with age. Sirt6 overexpres-
sion expanded life span in male mice [38]. Sirt6 knockout mice
exhibit an accelerated ageing phenotype and die prematurely.
Sirt6 specific depletion in the brain results in increased DNA
damage, Tau phosphorylation and learning defects [39].
3xTg/Pol+/ mice
DNA polymerase beta (Polb) is a primary polymerase involved
in BER. Disruption of Polb induced growth retardation and
post-natal lethality in mice. A 50% reduction in Polb levels
(heterozygous for Polb gene) aggravated the phenotypes of
3xTg Alzheimer’s Disease (AD) mice. Neuronal dysfunction,
cell death and memory impairment were also shown to be
more severe than in the 3xTg AD mice or Polb+/ mice.
Pathway comparison analysis of human and mouse micro-
array data revealed that the combined 3xTg/Polb+/ transgen-
ic mouse is more similar to human AD patients than the
3xTgAD or Polb+/ mice [40].
Telomere attrition mouse model
Telomere shortening is observed in all eukaryotes [41]. Mice
carrying a homozygous germ line deletion for the telomerase
RNA component gene (Terc) showed complete loss of Terc
expression and telomerase activity. For the Terc/mice, the
telomeres become shorter during successive generations of
mating due to the replication end-point problem, usually
resulting in phenotypic changes after the third generation.
Third generation Terc/mice showed impaired spatial learn-
ing memory, and accordingly, the dentate gyrus (DG) volume30 www.drugdiscoverytoday.comand brain weight were decreased in the Terc/ mice [42].
Further study revealed reduced neurogenesis in the DG and
loss of neurons in the hippocampus and frontal cortex in
third generation Terc/mice [43]. Telomere dysfunction also
led to reduced microglial numbers and cell body volume in
DG, nevertheless, telomere shortening did not affect micro-
glial proliferation or induce an ageing phenotype [42,43].
Terc/microglia also exhibited an enhanced pro-inflamma-
tory response to peripheral LPS stimulation. However, unlike
Ercc1D/microglia, this enhanced response is correlated with
brain infiltration and blood–brain barrier dysregulation rath-
er than age-related microglia priming [44]. Terc deficiency
was also studied in combination with several age-related
disease mouse models. Telomere shortening was shown to
accelerate the amyotrophic lateral sclerosis (ALS) phenotypes
in SOD1G93A transgenic mice and Parkinson’s disease (PD)
phenotypes in (Thy-1)-h[A30P] a-synuclein transgenic mice
[45,46]. Surprisingly, telomere shortening reduced AD amy-
loid pathology in APP23 transgenic mice [43].
Telomerase reverse transcriptase (TERT) is the catalytic sub-
unit of the telomerase complex. Its deficiency also induced
ageing phenotypes quite similar to Terc / mice [47]. What
differed is that TERT deficiency induced aggressive and depres-
sive behaviors in a mouse brain structure-specific manner [48].
Tert gene knockout mice also display impaired spatial memory,
dendritic development and neuritogenesis [49]. Detailed CNS
phenotypes of these mice are described in Table 1.
Mouse models with mitochondrial dysfunction
It is well accepted that mitochondria play a central role in
ageing and neurodegenerative diseases [50]. Commonly
used mouse models with mitochondrial dysfunction in-
clude dopaminergic neuron specific Twinkle transgenic
mice, mitochondrial late-onset neurodegeneration
(MILON) mice, mitochondrial quality control gene
Afg3l2, Spg7, Phb2 and HtrA2/Omi-deficient mice, apopto-
sis-inducing factor Aif deficient mice and mito-PstI trans-
genic mice all showed substantial brain ageing and
neurodegeneration phenotypes [51]. Detailed CNS phe-
notypes of these mice are described in Table 1. Due to
premature death of HtrA2/Omi deficient mice, this mouse
model is not discussed here [52].
Mouse models with deﬁcits in proteostasis
Loss of proteostasis is observed in many neurodegenerative
diseases such as AD and PD. In mammals, proteostasis is
maintained by chaperones and two proteolytic systems,
the ubiquitin-proteasome and the lysosome-autophagy sys-
tems [10]. Autophagy-deficient mice showed ageing related
changes and neurodegenerative changes that resemble those
associated with ageing [53], among them, Becn1, Atg7 and
FAK family-interacting protein of 200 kDa (FIP200) deficient
mice showed neurodegeneration phenotypes (see Table 1).
Vol. 25–26, 2017 Drug Discovery Today: Disease Models | Models of Neuroimmune and Neurodegenerative DiseasesDefects in the sphingomyelinases gene Smpd3 resulted in age-
dependent neuronal dysproteostasis in Smpd3/mice, caus-
ing accumulation of APP, Ab, and phosphorylated Tau (pTau)
in neurons. The deficient mice also showed age-dependent
decline of motor activity, coordination and cognitive ability
[54]. Endoplasmic reticulum (ER) is important to maintain
proteostasis, as approximately 30% of proteins are synthe-
sized and processed there. ER stress is also a common patho-
logical signature in a variety of diseases, including
neurodegenerative disease [55]. Binding immunoglobulin
protein (BiP) is central for ER function and mutant BiP mice
exhibited motor disabilities during ageing. Degeneration of
motoneurons and accumulations of ubiquitinated proteins
were also found in the spinal cord [56].
Mouse models with deﬁcits in nutrient sensing
The insulin/insulin-like growth factor 1 (Insulin/IGF1) signal-
ing pathway is evolutionarily conserved and involved in
growth, development, metabolic homoeostasis and also CNS
ageing [57]. IGF1 is a neuroprotective hormone that is mainly
produced in the liver. Conditional, liver-specific inactivation of
the Igf1 gene induced an age-associated decline in learning
memory. Further study identified astrocytosis and increased
neurochemical disturbances in the DG area [58]. Reduced hip-
pocampal IGF-1 receptor (IGF1R) expression is associated with
age-related decline in learning, and astrocyte-specific knockout
of IGF1R was demonstrated to induce impairments in working
memory[59].ForkheadboxO(FOXO)transcriptionfactorsplay
a pivotal role in the IIS/PI3K/Akt signaling pathway. They are
important determinants of ageing and longevity [60]. FOXO
expression progressively increases in ageing human and mouse
brains [61]. Conditional knockout of Foxo 1, 3, and 4 in neurons
and glia cells induced an accelerated ageing phenotype in mice,
manifested by axonal tract degeneration and gliosis [61].
Senescence accelerated mouse-prone (SAM-P) mice
The SAM-P mice are naturally occurring mouse lines that
display a series of accelerated ageing phenotypes. At present,
there are eight strains of SAM-P. It is noteworthy that each
SAM-P strain has relatively strain-specific pathological phe-
notypes [62]. Since SAM-P/8 and SAM-P/10 display deficits in
learning and memory, these strains were extensively used to
investigate CNS ageing. A variety of age-associated alterations
involving neurons, glia and blood brain barriers have been
identified in SAM-P/8 and SAM-P/10 mice brain. SAM-P/8
could also serve as an animal model for AD and other
dementias as age-related increases in pTau and amyloid ac-
cumulation were also observed in the hippocampus of SAMP8
mouse brains [63]. The 3xTg-AD transgenes in a SAM-P/8
background showed deficits in spatial memory and female-
specific aggravation of AD pathology characterized by activa-
tion of astrocytes and increased accumulation of pTau and
amyloid in the brain [64]. Some epigenetic alternations asso-ciated with ageing and neurodegeneration were also identi-
fied in the SAMP-P/8 brain [65,66].
Promising therapeutic targets
Although ageing itself is an inevitable process, interventions
could be applied to extend both lifespan and health-span. A
longevity study in monozygotic twins indicated that life span
is determined largely by environmental factors rather than
genetic factors [67]. Work on mouse models of ageing has not
only contributed to the identification of many of the molec-
ular pathways involved in ageing, but also have provided
possible targets for the treatment of age-related CNS decline.
Epigenetic signatures are proposed to function as biomarkers
of ageing, for example, the DNA methylome can help to
measure human ageing rates [5]. Epigenetic modifications
are considered to be dynamic and reversible, making it an
attractive therapeutic target. Chromatin modifying com-
pounds such as sirtuin modulators and histone deacetylase
inhibitors are thought to provide a promising treatment for
neurodegenerative diseases [68,69].
In recent years, senescent cells are recognized as a new
target for age-related disease. In mouse, clearance of
p16Ink4a-positive senescent cells was shown to delay age-
ing-associated phenotypes in BubR1H/Hmice [70]. Fuhrmann-
Stroissnigg et al. established a drug-screening platform to
identify senolytic compounds using Ercc1/ primary murine
embryonic fibroblasts. Through this platform, they success-
fully identified an HSP90 inhibitor, 17-DMAG, which could
extend health-span and delay the onset of several age-related
symptoms in Ercc1D/ mice [71]. Microglia are shown to
undergo age-dependent degeneration, increasingly display-
ing a primed or hyperreactive, pro-inflammatory phenotype
and a deficiency in phagocytosis and chemotaxis. Senescent
microglia are believed to be involved in switching normal
brain ageing to pathological ageing [72]. The rejuvenation of
senescent microglia was already shown to be a potential
druggable target [73]. However, so far, there is no evidence
whether microglia senolysis could restore normal function
and revert or halt CNS ageing phenotypes.
Dietary restriction increases lifespan or health-span in all
investigated eukaryote species [10]. A similar effect is seen
when the activity of nutrient-sensing pathways is reduced by
mutations or chemical inhibitors [74], indicating that nutri-
ent-sensing pathways could provide promising targets to slow
ageing. For example, the Insulin- and IGF-1-signaling path-
way, the mammalian target of rapamycin (mTOR) pathway
and the AMPK pathway are involved in nutrient sensing.
And, manipulation of these pathways could increase lifespan
and delay multiple aspects of ageing [10,75,76].
Conclusions
Studying brain ageing in humans is challenging due to very
limited or no access to healthy tissue, limited opportunitieswww.drugdiscoverytoday.com 31
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by confounding factors like environment, nutrition, medical
history, medication, education etc. The generation of mouse
models with uniform genetic backgrounds significantly con-
tributed to our understanding of ageing at the molecular
level. However, conclusions must be drawn with caution
because the results obtained from inbred mice may not
represent the species as a whole [77]. Also, the mouse models
cannot recapture all the brain ageing phenotypes in human,
nor reliably predict age-related changes in humans owing to
differences in the ageing process in human and mouse.
Though the mouse models described here have been used
to identify molecular mechanisms of ageing, and to identify
possible therapeutic targets, their use in the development of
therapies and in particular the translation to the human
situation is still not well developed [78]. In case of AD, for
example, gene mutations that lead to AD-like phenotypes in
young animals do not fully mimic human AD in older
patients and therefore the predictive value of testing drugs
in such models is limited [79].
Nonhuman primates are more similar to humans in how
they experience ageing processes, which include ageing re-
lated pathologies like cancer, diabetes, arthritis, cardiovascu-
lar disease, and neurological decline. However, their
substantial size, long lifespan, and the associated expense
are prohibitive factors in their large scale-use for research into
ageing. Nonetheless, they could provide a crucial component
between the bench and the bedside [80]. In this review, we
mainly focused on the functional consequences and patho-
logical changes resulting from conserved pathways dysfunc-
tion in brain ageing. Understanding how these conserved
pathways contribute to pathological ageing may help us to
get a better understanding of brain ageing and develop
possible treatment strategies. Finally, it is worth noting that
the ageing process involves multiple organs and tissues, and
the influence of peripheral organs on CNS ageing cannot be
ignored.
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